Phase I/II study of RGX-121 in patients with Mucopolysaccharidosis Type II (MPS II)

Trial Profile

Phase I/II study of RGX-121 in patients with Mucopolysaccharidosis Type II (MPS II)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs RGX 121 (Primary)
  • Indications Mucopolysaccharidosis II
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Jul 2016 New trial record
    • 05 Jul 2016 According to Regenxbio media release, company plans to submit an IND in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top